Ticker
AEZS

Price
5.30
Stock movement up
+0.02 (0.38%)
Company name
Aeterna Zentaris Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsverdi
25.74M
Ent verdi
-14.67M
Pris/omsetning
4.16
Pris/bok
0.48
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-
Etterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års avkastning
-69.28%
3 års avkastning
-53.29%
5 års avkastning
-35.57%
10 års avkastning
-50.97%
Sist oppdatert: 2022-08-25

UTBYTTE

AEZS betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning4.16
Pris til bok0.48
EV i forhold til salg-2.37

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall4.86M
EPS (TTM)-1.97
FCF per aksje (TTM)-1.88

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)6.19M
Bruttofortjeneste (TTM)6.05M
Driftsinntekter (TTM)-10.17M
Netto inntekt (TTM)-9.56M
EPS (TTM)-1.97
EPS (1 år fremover)-2.50

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)97.74%
Driftsmargin (TTM)-164.24%
Fortjenestemargin (TTM)-154.47%

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter63.60M
Netto fordringer2.17M
Samlede omløpsmidler67.10M
Goodwill7.98M
Immaterielle eiendeler612.00K
Eiendom, anlegg og utstyr0.00
Sum eiendeler76.34M
Leverandørgjeld1.02M
Kortsiktig/nåværende langsiktig gjeld165.00K
Sum kortsiktig gjeld5.67M
Sum gjeld23.18M
Aksjonærenes egenkapital53.16M
Netto varige driftsmidler44.57M

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)-9.00M
Kapitalutgifter (TTM)138.00K
Fri kontantstrøm (TTM)-9.13M
Utbetalt utbytte (TTM)0.00

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning-17.99%
Avkastning på eiendeler-12.53%
Avkastning på investert kapital-17.99%
Kontantavkastning på investert kapital-17.18%

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning5.30
Daglig høy5.39
Daglig lav5.24
Daglig volum49K
Tidenes høyeste94881.00
1 år analytikerestimat37.50
Beta1.71
EPS (TTM)-1.97
Utbytte per aksje-
Ex-div dato-
Neste dato for resultatpresentasjon2 Nov 2022

Nedsidepotensial

Loading...
Nedsidepotensial-data
AEZSS&P500
Nåværende prisfall fra toppnotering-99.99%-13.41%
Høyeste prisfall-100.00%-56.47%
Dato for høyeste fall15 Jun 20229 Mar 2009
Gj.snittlig fall fra topp-79.25%-11.38%
Gj.snittlig tid til ny topp918 days12 days
Maks tid til ny topp5486 days1805 days
SELSKAPSOPPLYSNINGER
AEZS (Aeterna Zentaris Inc) company logo
Markedsverdi
25.74M
Markedsverdi kategori
Small-cap
Beskrivelse
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Ansatte
0
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Klaus Paulini
Land
USA
By
Charleston
Aksjetype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
– Company plans to prioritize efforts to identify new strategic development and commercialization partner – Company is in a strong position that enables it to continue the ongoing pivotal Phase 3 stud...
29. august 2022
– Company ended the quarter with $58.2 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Aug. 03, 2022 (GLOBE NEWSWIRE) -...
3. august 2022
CytomX Therapeutics (CTMX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
28. juli 2022
TORONTO, ON, July 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing thera...
18. juli 2022
TORONTO, ONTARIO, July 15, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing ...
15. juli 2022
TORONTO, ONTARIO, July 06, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing ...
6. juli 2022
- Vote to approve share consolidation adjourned to July 6, 2022 TORONTO, ONTARIO, June 21, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a spe...
21. juni 2022
– Company advancing AIM Biologicals development program as a potential therapeutic treatment option for neuromyelitis optica spectrum disorder ("NMOSD") – Positive results presented at the 13th Intern...
13. juni 2022
Live video webcast on Wednesday, June 15th at 12:30 PM ET TORONTO, ONTARIO, June 09, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty...
9. juni 2022
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
3. juni 2022
Neste side